Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TROP2 targeting reveals therapy-driven cell state dynamics in colorectal cancer.

Nature·2026
Same author

Re-evaluating breast malignant pleural effusion: toward evidence-based, precision-aligned care with organoids.

Frontiers in bioengineering and biotechnology·2026
Same author

The patient journey and guideline-concordant care in colorectal cancer-is current practice enough?

Frontiers in medicine·2026
Same author

Improving preparedness for mass casualty incidents in hospitals: insights from a large-scale simulation exercise with geotracking and validated questionnaires.

BMC emergency medicine·2026
Same author

Human immunodeficiency virus-associated gut microbiome impacts systemic immunodeficiency and susceptibility to opportunistic gut infection.

Nature microbiology·2026
Same author

Ex Vivo Treatment Response Prediction in Multiple Myeloma: Assay Formats, Clinical Correlation, and Future Directions.

Cancers·2026
Same journal

Afatinib for Advanced Cancers Carrying an EGFR, HER2, or HER3 Mutation: An Open-Label, Phase II, Belgian Precision Study.

JCO precision oncology·2026
Same journal

Molecular Testing in Primary Advanced or Recurrent Endometrial Cancer: A Cost-Effectiveness Analysis.

JCO precision oncology·2026
Same journal

Patterns of Response to Immune Checkpoint Inhibitors in Sarcomas With High Tumor Burden and/or Mismatch Repair Deficiency.

JCO precision oncology·2026
Same journal

Multimodal Spatiotemporal Signature Integrating Pathomics and Longitudinal Magnetic Resonance Imaging Predicts Response to Neoadjuvant Therapy and Prognosis in Rectal Cancer.

JCO precision oncology·2026
Same journal

Time to Treatment Failure as an End Point in Pragmatic Oncology Trials: Association With Progression-Free Survival Across Randomized Studies.

JCO precision oncology·2026
Same journal

Genomic Landscape of GNAQ and GNA11 Mutations in Metastatic Solid Tumors: A Real-World Data Analysis.

JCO precision oncology·2026
See all related articles

Related Experiment Video

Updated: Jan 17, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.6K

Functional Precision Medicine Using MicroOrganoSpheres for Treatment Response Prediction in Advanced Colorectal

Roán Gobits1, Nikolai Schleußner2,3, Gavin R Oliver4

  • 1Xilis B.V., Utrecht, the Netherlands.

JCO Precision Oncology
|January 15, 2026
PubMed
Summary
This summary is machine-generated.

MicroOrganoSpheres (MOS) predict chemotherapy response in advanced colorectal cancer (CRC) with high accuracy. This 3D tumor model offers a scalable platform for precision medicine, guiding treatment decisions and improving patient outcomes.

More Related Videos

High-sensitivity Detection of Micrometastases Generated by GFP Lentivirus-transduced Organoids Cultured from a Patient-derived Colon Tumor
09:16

High-sensitivity Detection of Micrometastases Generated by GFP Lentivirus-transduced Organoids Cultured from a Patient-derived Colon Tumor

Published on: June 14, 2018

10.6K
Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
12:41

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Published on: December 23, 2022

5.7K

Related Experiment Videos

Last Updated: Jan 17, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.6K
High-sensitivity Detection of Micrometastases Generated by GFP Lentivirus-transduced Organoids Cultured from a Patient-derived Colon Tumor
09:16

High-sensitivity Detection of Micrometastases Generated by GFP Lentivirus-transduced Organoids Cultured from a Patient-derived Colon Tumor

Published on: June 14, 2018

10.6K
Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
12:41

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Published on: December 23, 2022

5.7K

Area of Science:

  • Oncology
  • Biotechnology
  • Precision Medicine

Background:

  • Advanced colorectal cancer (CRC) treatment relies on neoadjuvant chemotherapy, but 30-40% of patients experience treatment progression.
  • Limited scalable and reproducible tools exist for stratifying CRC patients and predicting chemotherapy response.
  • MicroOrganoSpheres (MOS) are droplet-encapsulated 3D tumor models enabling high-throughput drug testing.

Purpose of the Study:

  • To evaluate the potential of tumor-derived MOS for predicting chemotherapy response in colorectal cancer (CRC) patients.
  • To assess the scalability and reproducibility of MOS as a predictive tool for CRC treatment.
  • To investigate MOS's ability to guide up-front treatment selection in advanced CRC.

Main Methods:

  • Generated MOS droplets from 37 primary/metastatic tumor samples from 21 CRC patients.
  • Quantified MOS response to chemotherapy using AI-based imaging analysis.
  • Compared MOS drug sensitivity with clinical response (RECIST, DFS) and lesion-specific outcomes.

Main Results:

  • MOS chemoprediction assay demonstrated high reproducibility (CV ≤ 2.5%).
  • MOS drug sensitivity accurately predicted patient response (83% overall, 100% for primary tumors).
  • Sensitive MOS correlated with longer disease-free survival (DFS); MOS preserved intratumor heterogeneity and identified resistant clones.

Conclusions:

  • MOS technology provides a scalable, robust functional precision medicine platform for colorectal cancer (CRC).
  • The platform accurately predicts patient chemotherapy response, aiding clinical decision-making.
  • MOS offers insights into intrapatient and intratumor heterogeneity, crucial for personalized treatment.